Drug intelligence / Profile preview

lomedeucitinib

Development stage: Phase 2
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral

Overview

Lomedeucitinib (BMS-986322) is a selective tyrosine kinase 2 (TYK2) inhibitor developed by Bristol Myers Squibb. It is an oral small molecule drug with anti-inflammatory activity, primarily investigated for the treatment of moderate-to-severe psoriasis. TYK2 is a member of the Janus kinase family and plays a key role in cytokine signaling pathways involved in immune-mediated diseases. By selectively inhibiting TYK2, lomedeucitinib aims to block the signaling of pro-inflammatory cytokines implicated in psoriasis pathogenesis while minimizing off-target effects associated with broader JAK inhibition[1][2][3][5].

Targets

TYK2 (Tyrosine kinase 2)

Beyond the preview

Go deeper on lomedeucitinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lomedeucitinib.

Explore the full profile